Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

Guimarães-Walker, A; Mackie, N; McCormack, S; Hanke, T; Schmidt, C; Gilmour, J; Barin, B; McMichael, A; Weber, J; Legg, K; Babiker, A; Hayes, P; Gotch, F; Smith, C; Dally, L; Dorrell, L; Cebere, I; Kay, R; Winstone, N; Moore, S; Goonetilleke, N; Fast, P

Journal article

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

Abstract:: IAVI-006 was the first large randomised, double-blinded, placebo-controlled Phase I clinical trial to systematically investigate the prime-boost strategy for induction of HIV-1 specific CD8+ cytotoxic T-lymphocytes (CTL) in a factorial trial design using (i) priming with 0.5 mg or 2 mg of pTHr.HIVA DNA vaccine, followed by (ii) two booster vaccinations with 5 x 10(7) MVA.HIVA at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost). This study set the basis for later clinical trials and demonstrated the safety of these candidate HIV vaccines. The safety and immunogenicity results are presented and the lessons derived from this clinical trial are discussed.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Guimarães-Walker, A., Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B., McMichael, A., Weber, J., Legg, K., Babiker, A., Hayes, P., Gotch, F., Smith, C., Dally, L., Dorrell, L., Cebere, I., Kay, R., Winstone, N., … Fast, P. (2008). Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine, 26(51), 6671–6677.

MLA Style

Guimarães-Walker, A., et al. “Lessons from IAVI-006, a Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the PTHr.HIVA DNA and MVA.HIVA Vaccines in a Prime-Boost Strategy to Induce HIV-1 Specific T-Cell Responses in Healthy Volunteers.” Vaccine, vol. 26, no. 51, 2008, pp. 6671–77.

Chicago Style

Guimarães-Walker, A, N Mackie, S McCormack, T Hanke, C Schmidt, J Gilmour, B Barin, et al. 2008. “Lessons from IAVI-006, a Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the PTHr.HIVA DNA and MVA.HIVA Vaccines in a Prime-Boost Strategy to Induce HIV-1 Specific T-Cell Responses in Healthy Volunteers.” Vaccine 26 (51): 6671–77.
Share
Print